Month: August 2024

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided an update on its corporate activities and product pipeline. “We continue to focus on our Cloudbreak DFC platform with the advancement of CD388 and other programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Our Phase 2b study to evaluate the efficacy and safety of CD388, a long-acting drug candidate that provides season-long, universal protection from influenza, is on track to start in the fall of 2024...

New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. Bloch On track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarter In Q2 2024, increased product sales by 10% and reduced operating loss by 48% Achieved more than a quarter million CytoSorb treatments cumulatively delivered to date – a major company milestonePRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024.   Second Quarter 2024 Financial ResultsTotal revenue for Q2 2024, including product sales and grant income, was $9.9 million, an increase of 5% compared to $9.4 million in Q2 2023 Q2 2024 product sales were...

Second Quarter 2024 vs. Second Quarter 2023Revenue of $20.8 million compared to $20.5 million; Gross profit of $5.1 million compared to $4.6 million; Gross margin of 24.6% compared to 22.4%; Net income of $1.4 million compared to $1.2 million; Earnings per diluted share of $0.11 compared to $0.09; Adjusted EBITDA (1) of $2.6 million compared to $2.1 million; Cash flow used in operations of $(0.6) million compared to $0.0 million.Six Months 2024 vs. Six Months 2023Revenue of $39.9 million compared to $42.6 million; Gross profit of $8.7 million compared to $9.3 million; Gross margin of 21.7% compared to 21.8%; Net income of $1.6 million compared to $2.1 million; Earnings per diluted share of $0.12 compared to $0.17; Adjusted EBITDA (1) of $3.8 million compared to $4.3 million Cash flow used in operations of $(1.6) million compared...

Continuing progress on Corporate initiatives in conjunction with improving sequential results establishing solid foundation for growth and profitability in 2025 JACKSONVILLE, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), reported financial results for the second quarter (“Q2 2024”) ended June 30, 2024.Second Quarter 2024 and Recent Operational HighlightsClosed initial 5-Year support services and data sharing agreement with Class 1 railroad valued at $10.9 million. The agreement provides full data availability for 7 existing client portals. Additionally, we now have data available from an eighth portal from a Mexican railroad, which we plan to leverage all 8 portals for subscription marketing starting in Q3. Over 2.3 million comprehensive railcar scans were performed...

MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2024 and Recent Highlights: ClinicalPhase 3 ASPIRE clinical trial received favorable third independent safety review: DSMB recommended continuation without modification. Completed Oral Presentation at Digestive Disease Week (DDW): Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin American. Provided revised timing...

– Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 – – Reported Positive Preliminary Data from the Phase 2a Trial of SLS009 in r/r AML Demonstrating to Date Overall Response Rate (ORR) of 33%, 50%, and 100% in 60 mg QW, 30 mg BIW and 30mg BIW with ASXL1 Mutation Cohorts Respectively – – SLS009 Granted EMA Orphan Drug Designations and U.S. FDA Rare Pediatric Disease Designations – – $21 million of Gross Proceeds from Capital Raise Priced at a Premium to Market in August 2024 – NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical...

CHARLOTTE, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) — Cheetah Net Supply Chain Service Inc. (“Cheetah” or “the Company”) (Nasdaq CM: CTNT), a provider of warehousing and logistics services and a seller of parallel-import vehicles sourced from the U.S. market and sold into the People’s Republic of China (the “PRC”), today reported results for the quarter ended June 30, 2024 and provided a corporate update. Recent HighlightsChallenging market conditions in the PRC, first reported with respect to the Company’s financial performance during the second half of 2023, have continued into 2024. The Company’s three- and six- month financial results were impacted by these unfavorable market conditions, resulting in a significant decline in revenue. Adverse market conditions continue to severely depress or eliminate the margin between U.S. retail...

Grew revenue by 14% year-over-year to $87.9 million and non-GAAP revenue by 29% Generated a net loss of $34.0 million, representing net loss as a percent of revenue of 39%, and Adjusted EBITDA of $25.3 million, representing a 29% Adjusted EBITDA margin Announced Instacart as new IPN partner with revenue contribution expected to begin by end of year DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) — Ibotta, Inc. (NYSE: IBTA), a leading technology company providing digital promotions and performance marketing solutions, today announced financial results for the second quarter ended June 30, 2024. “Our strong second quarter results demonstrate that Ibotta’s pay-for-performance model is resonating with our clients and consumers,” said Ibotta CEO and founder, Bryan Leach. “In the current macroeconomic environment, now more than ever, CPG brands...